NewsBenzingaCEL-SCI、世界会議でMultikineの第3相試験から新たな術前データを発表;リンパ節転移が検出されない局所進行性原発腫瘍;腫瘍比率スコア10%未満 CEL-SCI、世界会議でMultikineの第3相試験から新たな術前データを発表;リンパ節転移が検出されない局所進行性原発腫瘍;腫瘍比率スコア10%未満 Benzinga 2026.10.26 12:07 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report